Research Overview
Human research on stevia has most frequently examined cardiovascular and glycemic outcomes, particularly blood pressure effects of the steviol glycoside stevioside in people with essential hypertension, and shorter-term effects on postprandial glucose/insulin responses and energy intake when stevia replaces sugar. The studies include multiple randomized, double-blind, placebo-controlled trials in Chinese hypertensive populations (1–2 years) using stevioside capsules (typically 250–500 mg three times daily), as well as trials in normotensive adults using rebaudioside A (e.g., 1000 mg/day for 4 weeks) and a smaller crossover-style feeding study comparing stevia- vs sucrose-containing preloads on intake and postprandial metabolism. A recent systematic review/meta-analysis (26 studies; n≈1439) further synthesizes evidence on glycemic indices, reporting modest reductions in blood glucose with stevia, with stronger signals in higher-risk groups (higher BMI, diabetes, hypertension), though with low certainty.
The strongest evidence in these studies supports a blood-pressure–lowering effect of stevioside in people with mild-to-moderate essential hypertension, with sustained reductions in systolic and diastolic blood pressure over 1–2 years and generally good tolerability and stable routine laboratory parameters. In contrast, studies in normotensive or low-normal blood pressure individuals (including a 4-week rebaudioside A trial) and in mixed groups without baseline abnormalities suggest little to no clinically meaningful effect on blood pressure or glycemic control under those conditions, consistent with an effect that may be more apparent in hypertensive populations. For glycemic outcomes, controlled feeding data indicate stevia can lower postprandial glucose and insulin compared with sucrose in the acute setting, and meta-analytic evidence suggests small average reductions in blood glucose, but the certainty is limited and effects appear heterogeneous across populations and study designs.
Key gaps include generalizability beyond the populations and formulations most studied (notably long-term stevioside capsule trials in Chinese hypertensive cohorts), and clearer differentiation of effects across specific steviol glycosides (stevioside vs rebaudioside A) and real-world dietary exposures (sweetener use in foods/beverages rather than capsule dosing). More high-quality, longer-duration randomized trials are needed in diverse ethnic groups and clinical contexts (type 1 and type 2 diabetes, obesity, prediabetes), with standardized dosing, rigorous ambulatory blood pressure and cardiometabolic endpoints, and assessment of clinically meaningful outcomes (e.g., antihypertensive medication needs, incident hypertension, cardiovascular events). Additional research should also address mechanisms (e.g., insulin secretion/sensitivity, vascular effects), inter-individual variability, and the certainty-limiting issues highlighted by the meta-analysis (risk of bias, heterogeneity, and publication bias).
1. What conditions has Stevia been studied for?
Hypertension (high blood pressure): Studied in Chinese adults with mild essential hypertension and with higher baseline BP (e.g., DBP 95–110 mmHg) using stevioside capsules for 1–2 years.
Glycemic control in diabetes: Studied in people with Type 1 diabetes and Type 2 diabetes (stevioside 250 mg three times daily for 3 months), and in broader mixed populations in a systematic review/meta-analysis.
Glycemic and insulin responses in overweight/obesity and healthy adults: Acute/postprandial studies comparing stevia-sweetened preloads vs sucrose/aspartame in lean and obese participants.
Hemodynamic effects in normotensive individuals: Rebaudioside A (1000 mg/day for 4 weeks) tested in adults with normal/low-normal BP.
Weight management-related outcomes: Food intake and satiety after stevia vs sucrose/aspartame preloads (lean and obese participants).
Cardiac structure outcomes in hypertension: Left ventricular mass index (LVMI) and left ventricular hypertrophy (LVH) assessed in a 2-year hypertension trial.
2. Does it work in treating those conditions? Summarize the evidence.
-
Hypertension: Evidence of benefit in hypertensive patients (stevioside).
1-year RCT (n=106): Stevioside 250 mg three times daily reduced BP after 3 months and the effect persisted for 1 year (SBP ~166 to ~153 mmHg; DBP ~105 to ~90 mmHg; P<0.05), with no significant changes in glucose/lipids and no significant adverse effects reported.
2-year RCT (n=174; 168 completed): Stevioside 500 mg three times daily reduced SBP/DBP vs baseline and vs placebo after 2 years (SBP ~150 to ~140; DBP ~95 to ~89; P<0.05). Self-monitored BP suggested onset within ~1 week and persistence throughout the study.
-
Blood pressure in normotensive people: No meaningful effect (rebaudioside A).
4-week RCT (n=100): Rebaudioside A 1000 mg/day did not significantly change seated BP, 24-hour ambulatory BP, MAP, or heart rate in adults with normal/low-normal BP.
3-month RCT in mixed groups: In people without diabetes and with normal/low-normal BP, stevioside 250 mg three times daily had no significant BP change from baseline.
-
Diabetes/glycemic control: Mixed evidence; small improvements in glucose in some contexts, but not consistent for HbA1c.
3-month RCT in Type 1 and Type 2 diabetes: Stevioside 250 mg three times daily showed no significant changes from baseline in glucose or HbA1c in either diabetes group; authors concluded no pharmacological effect at sweetener doses in these populations.
Systematic review/meta-analysis (26 studies, n=1439): Stevia was associated with a modest reduction in blood glucose (WMD -3.84; 95% CI -7.15 to -0.53; P=0.02), with low certainty evidence. No significant effects on insulin or HbA1c (certainty rated very low/low). Subgroup/dose-response signals suggested larger effects in higher BMI/diabetes/hypertension and at ≥3342 mg/day, and within ~1–4 months (<120 days).
Acute preload study (lean n=19; obese n=12): Stevia preloads reduced postprandial glucose vs sucrose (p<.01) and reduced postprandial insulin vs both aspartame and sucrose (p<.05) shortly after a meal preload; this supports an acute glycemic advantage vs sugar, but does not establish long-term diabetes treatment effects.
-
Weight management (energy intake): Evidence supports reduced daily calorie intake when replacing sucrose with stevia in a controlled setting.
Preload study: Despite lower-calorie stevia/aspartame preloads (290 kcal) vs sucrose preload (493 kcal), participants did not compensate by eating more later; total daily intake was lower with stevia vs sucrose (difference ~301 kcal; p<.01). This suggests a potential role in reducing energy intake when substituting for sugar.
3. What health benefits does it have?
-
Blood pressure reduction in people with hypertension (stevioside).
Both 1-year and 2-year randomized, double-blind, placebo-controlled trials in Chinese hypertensive patients reported clinically meaningful BP reductions with stevioside (250–500 mg three times daily).
In the 2-year trial, quality of life scores improved overall with stevioside vs placebo (P<0.001).
-
Possible reduction in risk/progression of left ventricular hypertrophy (LVH) in mild hypertension.
In the 2-year trial, fewer patients had LVH at study end in the stevioside group vs placebo (11.5% vs 34.0%; P<0.001), and fewer developed new LVH (6.5% vs 24.3%; P<0.001). Mean LVMI did not significantly change, so this finding should be interpreted cautiously but is potentially clinically relevant.
-
Lower postprandial glucose/insulin compared with sucrose in short-term testing.
In the preload study, stevia reduced postprandial glucose vs sucrose and reduced insulin vs sucrose and aspartame, suggesting metabolic advantages when replacing sugar in a meal context.
-
Potential support for calorie reduction when replacing sugar.
Participants did not compensate for the lower-calorie stevia preload by eating more later, resulting in lower total daily intake vs sucrose in that controlled experiment.
-
Modest average glucose lowering across studies (uncertain).
The meta-analysis found a small reduction in blood glucose (low certainty), with signals of greater benefit in higher-risk groups and at higher doses.
4. Does it have any downsides or side effects?
-
Adverse effects in these studies were minimal and generally similar to placebo.
In the 1-year hypertension RCT, no significant adverse effects were observed and quality of life did not deteriorate.
In the 2-year hypertension RCT, no significant difference in incidence of adverse effects vs placebo was noted; laboratory tests were similar between groups.
In the 3-month study across Type 1 diabetes, Type 2 diabetes, and non-diabetic normotensive participants, no side effects were observed in the treatment groups.
In the 4-week rebaudioside A trial in normotensive adults, the main finding was lack of hemodynamic change; no clinically important BP changes were seen (the study does not emphasize adverse events).
-
Potential “downside” is lack of efficacy in some populations/outcomes.
In people with Type 1 or Type 2 diabetes, a 3-month stevioside regimen did not improve glucose or HbA1c.
In normotensive adults, rebaudioside A did not lower BP, suggesting benefits may be limited to those with elevated BP.
-
Evidence limitations (important for safety interpretation).
Several positive BP trials were conducted in Chinese populations using specific stevioside capsule doses; generalizability to other populations, stevia formulations (e.g., beverages/packets), and real-world dietary patterns is uncertain based on these studies alone.
The meta-analysis rated certainty for glucose outcomes as low and for insulin/HbA1c as very low/low, indicating that future trials could change conclusions.
5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?
The studies reviewed here do not report pharmacogenomic analyses (e.g., outcomes stratified by genotype) and do not identify specific genetic variants that predict benefit or harm from stevia/stevioside/rebaudioside A.
No genotype-stratified efficacy data: The hypertension and glycemic studies summarized outcomes by clinical groups (hypertension status, diabetes status, BMI), not by genetic variation.
No genotype-stratified safety data: Adverse events were reported at the group level without genetic subgrouping.
Conclusion: Based on these studies alone, there is insufficient evidence to claim stevia is beneficial or harmful for any specific genetic variations.
References
-
Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in Type 1 and Type 2 diabetics
Luis A Barriocanal, Mafalda Palacios, Gilda Benitez, Sussam Benitez, Jorge T Jimenez (2008) -
A double-blind placebo-controlled study of the effectiveness and tolerability of oral stevioside in human hypertension
P Chan, B Tomlinson, Y J Chen, J C Liu, M H Hsieh (2000) -
Efficacy and tolerability of oral stevioside in patients with mild essential hypertension: a two-year, randomized, placebo-controlled study
Ming-Hsiung Hsieh, Paul Chan, Yuh-Mou Sue, Ju-Chi Liu, Toong Hua Liang (2003) -
The hemodynamic effects of rebaudioside A in healthy adults with normal and low-normal blood pressure
K C Maki, L L Curry, M C Carakostas, S M Tarka, M S Reeves (2008) -
Effects of stevia, aspartame, and sucrose on food intake, satiety, and postprandial glucose and insulin levels
Stephen D Anton, Corby K Martin, Hongmei Han, Sandra Coulon, William T Cefalu (2010) -
Effect of stevia on blood glucose and HbA1C: A meta-analysis
Marzieh Zare, Mobina Zeinalabedini, Soraiya Ebrahimpour-Koujan, Nick Bellissimo, Leila Azadbakht (2024)
This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!